Program
brensocatib
Also written as “Brensocatib”, “Brensocatib 10 mg” and “Brensocatib 25 mg”.
Its studies are mostly in Bronchiectasis · Nasal Polyps · Hidradenitis Suppurativa · Cystic Fibrosis · Renal Insufficiency, led by 2 companies.
Drug pageBrensocatib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Insmedits history only | 151 open or running | phase 3since Oct 14, 2020 | Jul 11, 2017 | Nov 25, 2026phase 1 · NCT07859007 |
| AstraZeneca | 20 open or running | phase 1since Nov 3, 2014 | Nov 3, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 3, 2014First study: phase 1 study in Safety, Pharmacokinetics, Pharmacodynamics, Food EffectFirst studyNCT02303574 · 89 enrolled · United Kingdom
- Jan 11, 2016Phase 1 study in Healthy SubjectsNCT02653872 · 15 enrolled · United Kingdom
- Jun 9, 2019Named brensocatibINNProposed as its International Nonproprietary Name in WHO's List 121
TargetBeta
“An orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), ”NCIt, by rule
“Dipeptidyl peptidase I inhibitor”ChEMBL 37, by rule
Other programs on CTSC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| verducatib | Boehringer Ingelheim | phase 3 | 21 |
| RSS0343 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 2 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02653872Healthy Subjects · United Kingdom | 1 | Completed | Apr 13, 2016 | 15 |
| NCT02303574Safety, Pharmacokinetics, Pharmacodynamics, Food Effect · United Kingdom | 1 | Completed | Aug 3, 2016 | 89 |
How it is read
Names in the registry
- “Brensocatib”, 10 entries
- “Brensocatib 10 mg”, 2 entries
- “Brensocatib 25 mg”, 2 entries
- “Brensocatib Oral Solution”, 1 entry
- “Brensocatib Oral Tablet”, 1 entry
Codes read as this program: AZD7986.
Conditions, from the studies’ own filings
- Bronchiectasis, 2 studies
- Nasal Polyps, 1 study
- Hidradenitis Suppurativa, 1 study
- Cystic Fibrosis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.